In this article
In addition to surgery, chemotherapy is the main treatment for gastric cancer
At present, the treatment of gastric cancer is still mainly surgical resection. Because of the majority of patients with gastric cancer admitted to advanced cancer. The surgical resection rate is only about 50%. Moreover, the efficacy of simple surgery is very poor, and the five-year survival rate after surgery is only 20% to 30%. As an important part of comprehensive treatment, chemotherapy is one of the important methods for treating gastric today.
Commonly used drugs for gastric cancer: 5-fluorouracil, cisplatin, oxaliplatin, etoposide, doxorubicin, epirubicin, mitomycin, paclitaxel, docetaxel, etc. Clinically, a combination of multiple chemotherapy regimens is commonly used, such as:
CF scheme (cisplatin / 5FU)
ECF scheme (epirubicin / cisplatin / 5FU) and its improved scheme (oxaliplatin instead of cisplatin and / or capecitabine instead of 5FU)
ELF scheme (Etoposide / Calcium Folinate / 5FU)
FAM scheme ( 5FU / / Mitomycin)
DCF scheme (Docetaxel / Cisplatin / 5-FU)
Common side effects and treatment measures of chemotherapy
Most patients with gastric cancer have varying degrees of nausea, vomiting, and anorexia 1-6 hours after medication , and a few have delayed reactions. Anti-emetic drugs such as glastron or azastron should be given routinely before and after chemotherapy as directed by your doctor. In addition, adjust the eating time according to the individual situation of the patient, eat a small number of meals, eat a light diet, and avoid eating foods that are too strong, greasy, and easy to produce gas. Most patients after total gastrectomy have mild or heavy symptoms of esophageal reflux. Do not lie down immediately after a meal. Raise the head of the bed 10-20 degrees during sleep. At the same time, family members should not eat too strong in the patient’s room. Greasy food, so as not to cause adverse stimulation to patients, try to keep patients in good mood.
The advent of targeted drugs changes the treatment situation
With the approval of targeted drugs, many patients who are eligible for targeted drugs have avoided the pain of chemotherapy and do not need to be infused in hospitals throughout the day. The treatment effect is greatly improved and the quality of life is greatly improved.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.